Moonwalk reloads with $70M and new RNAi prospects for obesity

Moonwalk reloads with $70M and new RNAi prospects for obesity

The California biotech plans to bring its first drug, enabled by licensing technology from a Chinese drugmaker, into clinical testing for obesity by the end of 2027.

Moonwalk Biosciences Closes $70 Million Series B

Moonwalk Biosciences has closed a $70 million Series B to advance its adipose-targeted RNAi platform toward first-in-human studies.

Moonwalk to Use $70 Million to Develop RNAi Therapies for Obesity, Cardiometabolic Disease

New financing will help Moonwalk Biosciences expand its pipeline of siRNA medicines targeting adipose tissue while building out its proprietary drug discovery platform. The post Moonwalk to Use $70 Million to Develop RNAi Therapies for Obesity, Cardiometabolic Disease appeared first on GEN - Genetic Engineering and Biotechnology News.